-
EP4013381
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4013381
| EP4013381 - IMPLANTABLE CAPSULE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 20.05.2022 Database last updated on 15.11.2024 | |
| Former | The international publication has been made Status updated on 19.02.2021 | ||
| Former | unknown Status updated on 17.08.2020 | Most recent event Tooltip | 22.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Release Therapeutics SA Avenue de Sécheron 15 1202 Genève / CH | For all designated states Les Hôpitaux Universitaires de Genève Rue Gabrielle-Perret-Gentil 4 1205 Geneva / CH | For all designated states UNIVERSITE DE GENEVE 24 rue du Général Dufour 1211 Geneva 4 / CH | [2024/01] |
| Former [2022/25] | For all designated states MaxiVAX SA Avenue de Sécheron 15 1202 Genève / CH | ||
| For all designated states Les Hôpitaux Universitaires de Genève Rue Gabrielle-Perret-Gentil 4 1205 Geneva / CH | |||
| For all designated states UNIVERSITE DE GENEVE 24 rue du Général Dufour 1211 Geneva 4 / CH | Inventor(s) | 01 /
LATHUILIÈRE, Aurélien Rue du Vidollet 43 1202 Geneva / CH | 02 /
GROGG, Julien Rue Madeleine 16 1003 Lausanne / CH | 03 /
MACH, Nicolas Route d'Hermance 153 1245 Collonge-Bellerive / CH | [2022/25] | Representative(s) | reuteler & cie SA Chemin de la Vuarpillière 29 1260 Nyon / CH | [2022/25] | Application number, filing date | 20753377.9 | 12.08.2020 | [2022/25] | WO2020EP72673 | Priority number, date | EP20190191868 | 14.08.2019 Original published format: EP 19191868 | [2022/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021028502 | Date: | 18.02.2021 | Language: | EN | [2021/07] | Type: | A1 Application with search report | No.: | EP4013381 | Date: | 22.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application. | [2022/25] | Search report(s) | International search report - published on: | EP | 18.02.2021 | Classification | IPC: | A61K9/00, A61F2/02, A61K35/12, A61L27/38 | [2022/25] | CPC: |
A61K38/193 (EP,CN,KR,US);
A61K9/0024 (EP,CN,KR,US);
A61K9/48 (CN,KR);
A61K35/12 (EP,CN,KR);
A61K35/15 (CN);
A61K35/34 (US);
A61L27/26 (US);
A61L27/3826 (US);
A61P35/00 (EP,CN,KR);
A61F2/022 (EP,KR);
A61K2035/126 (EP);
A61K2035/128 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/25] | Title | German: | IMPLANTIERBARE KAPSEL | [2022/25] | English: | IMPLANTABLE CAPSULE | [2022/25] | French: | CAPSULE IMPLANTABLE | [2022/25] | Entry into regional phase | 01.03.2022 | National basic fee paid | 01.03.2022 | Designation fee(s) paid | 01.03.2022 | Examination fee paid | Examination procedure | 01.03.2022 | Examination requested [2022/25] | 01.03.2022 | Date on which the examining division has become responsible | 21.07.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 01.03.2022 | Renewal fee patent year 03 | 20.07.2023 | Renewal fee patent year 04 | 21.06.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2017064571 (MAXIVAX SA [CH]); | by applicant | WO2014173441 | WO2017064571 |